News &amp; Updates

Ranitidine use not linked to increased cancer incidence

Individuals with ranitidine exposure do not appear to be at increased risk of cancer compared with those who have exposure to other histamine-2 receptor antagonists (H2RAs), according to a study.

Ranitidine use not linked to increased cancer incidence

Dabrafenib-trametinib combo improves response in BRAF V600-mutant paediatric glioma

04 Oct 2023 by

First-line treatment with dabrafenib plus trametinib significantly increased overall response rate (ORR) in paediatric patients with low-grade glioma harbouring BRAF V600 mutations compared with standard chemotherapy, according to a recent study.

Dabrafenib-trametinib combo improves response in BRAF V600-mutant paediatric glioma

Heavy alcohol use among hepatitis C patients does not weaken response to DAAs

Among patients with hepatitis C virus (HCV) infection, the likelihood of achieving sustained virologic response (SVR) with direct-acting antivirals (DAAs) does not appear to be reduced among those who use alcohol or have alcohol use disorder (AUD), according to a study.

Heavy alcohol use among hepatitis C patients does not weaken response to DAAs

LDL-C reduction prevents CVD in older adults

Lowering bad cholesterol can help prevent major vascular events in older individuals aged ≥70 years similarly as those aged <70 years, suggests a recent study.

LDL-C reduction prevents CVD in older adults

Efinopegdutide beats semaglutide at reducing liver fat in NAFLD patients

Treatment with the glucagon-like peptide-1 (GLP-1)/glucagon receptor co-agonist efinopegdutide results in a greater decrease in liver fat content (LFC) relative to the GLP-1 receptor agonist semaglutide in patients with nonalcoholic fatty liver disease (NAFLD), results of a phase IIa trial have shown.

Efinopegdutide beats semaglutide at reducing liver fat in NAFLD patients

03 Oct 2023

Do alpha-1 receptor blockers prevent severe COVID-19?

Frequent use of alpha-1 receptor blockers neither increases nor reduces the risk of uncomplicated or severe COVID-19 hospitalization in older men with or without benign prostatic hyperplasia (BPH), reveals a recent study.

Do alpha-1 receptor blockers prevent severe COVID-19?

03 Oct 2023

Serplulimab-chemo shows promise for squamous NSCLC

Patients with previously untreated, locally advanced, or metastatic squamous non-small-cell lung cancer (NSCLC) may derive benefit from the addition of the novel anti-PD-1 monoclonal antibody serplulimab to chemotherapy, according to the final analysis of the phase III ASTRUM-004 study.

Serplulimab-chemo shows promise for squamous NSCLC

03 Oct 2023

Female sex predictive of LDL-C goal underachievement

Among high-risk individuals, women are less likely than men to achieve the guideline-recommended low-density lipoprotein cholesterol (LDL-C) target, as shown in a study.

Female sex predictive of LDL-C goal underachievement

T-DXd shows meaningful and durable responses in previously treated HER2-mutant mNSCLC